Abstract: OBJECTIVE To analyze risk factors and therapeutic strategies for gastrointestinal bleeding during the treatment of antiplatelet agents and anti-coagulants. METHODS Clinical pharmacists made a systermatic analysis through a specific case. RESULTS Dual anti-platelet, warfarin, irregular INR-testing, elder, lost preventive using of pump inhibitors, which were all the reasons to result in gastrointestinal bleeding. The patient's bleeding symptoms had an effective control vias hemostatic, transfusions and the stopping using of antiplatelet agents and anticoagulants. CONCLUSION For people at high risk of gastrointestinal bleeding, proton pump inhibitors should be given timely as a prevention stratagem at least 3 months. The new protective agent of gastric mucosa such as rebamipide is useful for the primary prevention of gastric mucosal injury and can be considered as an alternative in the treatment of proton pump inhibitors.